检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).

Sophie Postel-Vinay,Vincent K Lam,Willeke Ros,Todd M Bauer,Aaron R Hansen,Daniel C Cho,F Stephen Hodi,Jan H M Schellens,Jennifer K Litton,Sandrine Aspeslagh,Karen A Autio,Frans L Opdam,Meredith McKean,Neeta Somaiah,Stephane Champiat,Mehmet Altan,Anna Spreafico,Osama Rahma,Elaine M Paul,Christoph M Ahlers,Helen Zhou,Herbert Struemper,Shelby A Gorman,Maura Watmuff,Kaitlin M Yablonski,Niranjan Yanamandra,Michael J Chisamore,Emmett V Schmidt,Axel Hoos,Aurelien Marabelle,Jeffrey S Weber,John V Heymach

Journal for immunotherapy of cancer（2023）

引用 6|浏览38
暂无评分
摘要
NCT02528357.
更多
查看译文
关键词
antibodies, neoplasm,biomarkers, tumor,clinical trials as topic,costimulatory and inhibitory T-cell receptors,immunotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要